Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

The company plans to evaluate its Allurion Program with GLP-1 agonists to address muscle loss concerns and promote healthier weight loss. Allurion entered into a securities purchase agreement to ...

Allurion Technologies (NYSE:ALUR) climbed 200% in the morning hours on Friday, adding to its strong post-market gains yesterday, even after the weight loss product developer announced plans to ...

Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Shantanu Gaur, the founder and chief executive of Allurion, said the goal of the study would be to prove that combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy would ...

NATICK, Mass., January 24, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...

09:42 EST Allurion Technologies (ALUR) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best ...

09:36 EST Allurion Technologies (ALUR) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

NATICK, Mass., January 23, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...